Bicara Therapeutics Names Jennifer Larson New CFO

Bicara Therapeutics Inc. has appointed Jennifer Larson as its new Chief Financial Officer, effective August 12, 2026. Her compensation package includes an inducement grant of stock options for 285,000 shares. This leadership change is a routine corporate development for the biotechnology firm.